LifeStance Health Group Inc has a consensus price target of $8.44 based on the ratings of 8 analysts. The high is $10 issued by Goldman Sachs on December 16, 2024. The low is $7 issued by Barclays on November 11, 2024. The 3 most-recent analyst ratings were released by Goldman Sachs, Barclays, and UBS on December 16, 2024, November 11, 2024, and August 15, 2024, respectively. With an average price target of $8.17 between Goldman Sachs, Barclays, and UBS, there's an implied 20.63% upside for LifeStance Health Group Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
12/16/2024 | Buy Now | 47.71% | Goldman Sachs | Jamie Perse60% | → $10 | Upgrade | Neutral → Buy | Get Alert |
11/11/2024 | Buy Now | 3.4% | Barclays | Stephanie Davis40% | $6 → $7 | Maintains | Underweight | Get Alert |
08/15/2024 | Buy Now | 10.78% | UBS | Kevin Caliendo72% | $9 → $7.5 | Maintains | Neutral | Get Alert |
08/09/2024 | Buy Now | -11.37% | Barclays | Stephanie Davis40% | $8 → $6 | Maintains | Underweight | Get Alert |
04/22/2024 | Buy Now | 47.71% | Morgan Stanley | Ricky Goldwasser78% | $10 → $10 | Reiterates | Overweight → Overweight | Get Alert |
03/06/2024 | Buy Now | 32.94% | Jefferies | Brian Tanquilut45% | $8 → $9 | Maintains | Buy | Get Alert |
03/04/2024 | Buy Now | 32.94% | Goldman Sachs | Jamie Perse60% | $8 → $9 | Maintains | Neutral | Get Alert |
02/29/2024 | Buy Now | 18.17% | Barclays | — | $7 → $8 | Maintains | Underweight | Get Alert |
11/22/2023 | Buy Now | 18.17% | Goldman Sachs | Jamie Perse60% | $9 → $8 | Maintains | Neutral | Get Alert |
11/17/2023 | Buy Now | 18.17% | JP Morgan | Lisa Gill59% | $10 → $8 | Maintains | Neutral | Get Alert |
08/10/2023 | Buy Now | 47.71% | JP Morgan | Lisa Gill59% | $9 → $10 | Maintains | Neutral | Get Alert |
07/13/2023 | Buy Now | 47.71% | Morgan Stanley | Ricky Goldwasser78% | $10 → $10 | Reiterates | Overweight → Overweight | Get Alert |
05/19/2023 | Buy Now | 32.94% | Goldman Sachs | Jamie Perse60% | $8 → $9 | Maintains | Neutral | Get Alert |
05/11/2023 | Buy Now | 47.71% | Morgan Stanley | Ricky Goldwasser78% | $8 → $10 | Maintains | Overweight | Get Alert |
01/06/2023 | Buy Now | 18.17% | Morgan Stanley | Ricky Goldwasser78% | → $8 | Upgrade | Equal-Weight → Overweight | Get Alert |
11/15/2022 | Buy Now | 18.17% | Goldman Sachs | Jamie Perse60% | $9 → $8 | Maintains | Neutral | Get Alert |
11/14/2022 | Buy Now | 18.17% | Cowen & Co. | Gary Taylor59% | $10 → $8 | Maintains | Outperform | Get Alert |
11/07/2022 | Buy Now | — | Jefferies | Brian Tanquilut45% | — | Assumes | → Buy | Get Alert |
08/22/2022 | Buy Now | 47.71% | Cowen & Co. | Gary Taylor59% | $11 → $10 | Maintains | Outperform | Get Alert |
05/10/2022 | Buy Now | 18.17% | Morgan Stanley | Ricky Goldwasser78% | $10 → $8 | Maintains | Equal-Weight | Get Alert |
The latest price target for LifeStance Health Gr (NASDAQ:LFST) was reported by Goldman Sachs on December 16, 2024. The analyst firm set a price target for $10.00 expecting LFST to rise to within 12 months (a possible 47.71% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for LifeStance Health Gr (NASDAQ:LFST) was provided by Goldman Sachs, and LifeStance Health Gr upgraded their buy rating.
The last upgrade for LifeStance Health Group Inc happened on December 16, 2024 when Goldman Sachs raised their price target to $10. Goldman Sachs previously had a neutral for LifeStance Health Group Inc.
There is no last downgrade for LifeStance Health Gr.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LifeStance Health Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LifeStance Health Gr was filed on December 16, 2024 so you should expect the next rating to be made available sometime around December 16, 2025.
While ratings are subjective and will change, the latest LifeStance Health Gr (LFST) rating was a upgraded with a price target of $0.00 to $10.00. The current price LifeStance Health Gr (LFST) is trading at is $6.77, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.